Population pharmacokinetics of belantamab mafodotin, a BCMA‐targeting agent in patients with relapsed/refractory multiple myeloma

• Main Authors: Chetan Rathi (Author), Jon Collins (Author), Herbert Struemper (Author), Joanna Opalinska (Author), Roxanne C. Jewell (Author), Geraldine Ferron‐Brady (Author)
• Formato: Livro
• Publicado em: Wiley, 2021-08-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Abstract Belantamab mafodotin (belamaf) is an antibody-drug conjugate (ADC) targeting B‐cell maturation antigen (BCMA). Nonlinear mixed‐effects models were developed to characterize the population pharmacokinetics (PopPK) of ADC, total monoclonal antibody (mAb), and cysteine‐maleimidocaproyl‐MMAF (c...